Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements episode artwork

EPISODE · Apr 10, 2016 · 0 MIN

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

from GRACEcast · host cancerGRACE Meetings

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Episode metadata supplied by the publisher feed · Published Apr 10, 2016

Embed this episode

NOW PLAYING

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

0:00 0:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 0 minutes long.

When was this GRACEcast episode published?

This episode was published on April 10, 2016.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!